[Form 4] CorMedix Inc. Insider Trading Activity

Rhea-AI Filing Summary

CorMedix Inc. insider Beth Zelnick Kaufman reported multiple transactions on 09/09/2025. She acquired 50,000 shares by exercising options at an exercise price of $3.30 (options originally granted 12/12/2023, vesting over four years). On the same date she disposed of 49,600 shares at a weighted average price of $13.41 and 400 shares at $12.82. Following these trades her beneficial ownership is reported as 180,418 shares.

Positive

• Acquired 50,000 shares by exercising stock options at an exercise price of $3.30 on 09/09/2025
• Options grant disclosed: options were granted on 12/12/2023 and vest over four years in equal instalments

Negative

• Disposed of 50,000 shares on 09/09/2025 (49,600 shares at a weighted average price of $13.41 and 400 shares at $12.82), reducing beneficial ownership from 230,418 to 180,418
• Sales executed across a price range of $12.83 to $13.82 (weighted average reported), indicating multiple trades rather than a single block sale

Insights

Financial Analyst

TL;DR: Insider exercised options and sold an equal number of shares same day, leaving a net reduction in reported holdings.

The filing shows exercise of 50,000 option-derived shares at $3.30 and near-immediate dispositions totaling 50,000 shares at weighted prices of $12.82–$13.82 (reported weighted average $13.41). The options were granted 12/12/2023 and vest over four years. Reported beneficial ownership after the transactions is 180,418 shares. For investors this is a clear record of non-derivative acquisition via exercise and concurrent market sales; the filing contains precise quantities and prices without further commentary.

Corporate Governance Expert

TL;DR: Transactions are properly disclosed: option exercise followed by open-market sales, with signature and explanatory footnotes included.

The Form 4 includes required disclosures: transaction codes, exercise price, grant date, vesting schedule, and an explanation that sales executed across prices $12.83–$13.82 with a weighted average reported. The form is signed and dated 09/11/2025. Documentation appears complete for Section 16 reporting; no amendment or missing procedural details are evident in the submitted content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zelnick Kaufman Beth

(Last) (First) (Middle)

C/O CORMEDIX INC.

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		M		50,000	A	$3.3	230,418	D
Common Stock	09/09/2025		S		49,600	D	$13.41(1)	180,818	D
Common Stock	09/09/2025		S		400	D	$12.82	180,418	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$3.3	09/09/2025		M			50,000	(2)	12/11/2033	Common Stock	50,000	$0	150,000	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $12.83 to $13.82. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

2. These options were granted on 12/12/2023. These options vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date.

	/s/ Beth Zelnick Kaufman	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Beth Zelnick Kaufman report for CRMD on 09/09/2025?

She acquired 50,000 shares by exercising options at $3.30 and disposed of 49,600 shares at a weighted average price of $13.41 and 400 shares at $12.82.

How many CorMedix (CRMD) shares does the reporting person own after the transactions?

The filing reports total beneficial ownership of 180,418 shares following the reported transactions.

When were the options that were exercised granted and what are their vesting terms?

The options were granted on 12/12/2023 and vest over four years in four equal annual installments, subject to continued employment.

What price range did the reported sales occur at according to the Form 4?

The sales were executed across prices ranging from $12.83 to $13.82; the filing reports a weighted average price of $13.41 for the 49,600-share sale.

Is the Form 4 signed and dated?

Yes, the Form 4 is signed by /s/ Beth Zelnick Kaufman and dated 09/11/2025.